The cognate receptor of acyl‐ghrelin, GHS‐R1a, is expressed not only in multiple areas of the brain but also in peripheral tissues, including the stomach, adrenal and pituitary gland, pancreas, intestines, and liver.[7, 35] Adverse effects such as somnolence, a warm feeling, facial warmth, abdominal pain, emesis, and vertigo were observed after systemic administration of ghrelin.[36, 37] Taken together, parenteral delivery of ghrelin for treatment of CNS diseases is not preferred and may necessitate the use of high doses, resulting in systemic toxicity and undesired side effects. The gene discussed is GHRL; the disease is Vertigo.